Osteoporosis prevention and management: An evidence-based review

Clinical Obstetrics and Gynecology

Volumn 51, Issue 3, 2008, Pages 556-563

  Kleerekoper, M ^a,c   Gold, Deborah T ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c ST JOSEPH MERCY HOSPITAL   (United States)

Author keywords

Menopause; Osteoporosis; Peak adult bone mass

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALENDRONIC ACID; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; IBANDRONIC ACID; OSTEOCALCIN; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ARTICLE; BONE DENSITY; BONE REMODELING; DUAL ENERGY X RAY ABSORPTIOMETRY; EVIDENCE BASED PRACTICE; HOT FLUSH; HUMAN; LABORATORY TEST; OSTEOLYSIS; PATIENT MONITORING; PHYSICAL EXAMINATION; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; PROPHYLAXIS; THROMBOEMBOLISM; AGED; DRUG EFFECT; EVIDENCE BASED MEDICINE; FEMALE; METHODOLOGY; MIDDLE AGED; PHOTON ABSORPTIOMETRY; PHYSIOLOGY; RADIOGRAPHY; REVIEW;

ABSORPTIOMETRY, PHOTON; AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 54449087710     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/GRF.0b013e3181809ae0     Document Type: Article

References (22)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. JAMA. 2001;285:785-795.
2. Kimber CM, Grimmer-Somers KA. Evaluation of current practice: compliance with osteoporosis clinical guidelines in an outpatient fracture clinic. Aust Health Rev. 2008;32:34-43. PMID: 18241147.
3. Silverman SL, Gold DT, Cramer JA. Reduced fracture rates observed only in patients with proper persistence and compliance with bisphosphonate therapies. South Med J. 2007;100:1214-1218. PMID: 18090964.
4. Kothawala P, Badamgarav E, Ryu S, et al. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc. 2007; 82:1493-1501. PMID: 18053457.
5. Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int. 2007;19:811-818. PMID: 17999022.
6. Kanis JA, Johnell O, Oden A, et al. Risk of hip fracture according to World Health Organization criteria for osteoporosis and osteopenia. Bone. 2000;27:585-590. PMID: 11062343.
7. Kanis JA, Johnell O, Oden A, et al. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int. 2001;12:989-995. PMID: 11846333.
8. Kanis JA, Johnell O, De Laet C, et al. International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res. 2002;17: 1237-1244. PMID: 12096837.
9. De Laet C, Oden A, Johnell O, et al. The impact of the use of multiple risk factors on case finding strategies: a mathematical framework. Osteoporos Int. 2005;16: 313-318. PMID: 15241584.
10. Tosteson AN, Melton LJ III, Dawson-Hughes B, et al; National Osteoporosis Foundation Guide Committee. Costeffective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int. 2008;19:437-447. PMID: 18292976.
11. Dawson-Hughes B, Tosteson AN, Melton LJ III, et al.; National Osteoporosis Foundation Guide Committee. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int. 2008;19:449-458. PMID: 18292975.
12. Jones G, Nguyen TV. Associations between maternal peak bone mass and bone mass in prepubertal male and female children. J Bone Miner Res. 2000;15: 1998-2004. PMID: 11028453.
13. Ferrari S, Rizzoli R, Slosman D, et al. Familial resemblance for bone mineral mass is expressed before puberty. J Clin Endocrinol Metab. 1998;83:358-361. PMID: 9467541.
14. Garnero P, Sornay-Rendu E, Duboeuf F, et al. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study. J Bone Miner Res. 1999;14:1614-1621. PMID: 10469291.
15. Doren M, Nilsson JA, Johnell O. Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis. Hum Reprod. 2003;18:1737-1746. PMID: 12871893.
16. Kanis JA, Burlet N, Cooper C, et al; on behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008;19:399-428. PMID: 18266020.
17. Barlow DH. Osteoporosis guidelines. Climacteric. 2007;10(suppl 2):79-82. PMID: 17882679.
18. North American Menopause Society. Management of osteoporosis in post-menopausal women: 2006 position statement of The North American Menopause Society. Menopause. 2006;13:340-367; quiz 368-369. PMID: 16735931.
19. AACE Osteoporosis Task Force. American Association of Clinical Endocrinol-ogists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract. 2003;9:544-564. No abstract available. Erratum in: Endocr Pract. 2004;10:90. PMID: 14715483.
20. U.S. Preventive Services Task Force. Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: recommendations and rationale. Ann Intern Med. 2002;137: 834-839. Summary for patients in: Ann Intern Med. 2002;137:I48. PMID: 12435221.
21. Brookhart MA, Avorn J, Katz JN, et al. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am J Med. 2007;120: 251-256.
22. Black DM, Schwartz AV, Ensrud KE, et al; FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296:2927-2938. PMID: 17190893.